Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000064.xml
psychoneuro 2005; 31(1): 46-52
DOI: 10.1055/s-2005-863101
DOI: 10.1055/s-2005-863101
Brennpunkt
© Georg Thieme Verlag Stuttgart · New York
Psychopharmaka-Verordnungen - Ergebnisse und Kommentare zum Arzneiverordnungsreport 2004
Further Information
Publication History
Publication Date:
01 February 2005 (online)
Zusammenfassung
Auch in diesem Jahr gibt der jährliche Arzneiverordnungsreport (Schwabe U, Paffrath D (Hrsg). Arzneiverordnungsreport 2004. Berlin, Heidelberg: Springer-Verlag, 2004, ISBN 3-540-21359-7) wichtige und spannende Informationen über das Verordnungsverhalten der niedergelassenen Ärzteschaft. Der Report übt im Vergleich zu früheren Ausgaben eine neue, eher nüchtern-wissenschaftliche Zurückhaltung in seinen Interpretationen. Allerdings fallen doch gelegentlich Widersprüche auf, die vermutlich den unterschiedlichen Autorenschaften zuzuschreiben sind.
Literatur
- 1 Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. International Journal of Psychiatry in Clinical Practice. 2003; 7 259-268
- 2 Barbui C, Campomori A, D'Avanzo B, Negri E, Garattini S. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol. 1999; 34 152-156
- 3 Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001; 10 525-530
- 4 Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004; 363 2105-2115
- 5 Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60 553-64
- 6 Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K, Gardner D, Faulding J, Madeley R. Deliberate self-harm and antidepressant drugs: Investigation of a possible link. Br J Psychiatry. 2000; 177 551-556
- 7 Fritze J. Innovative Therapien erfordern zusätzliche finanzielle Ressourcen - Teil III (Antidepressiva). Neurotransmitter. 2001; 12 33-39
- 8 Fritze J. Innovative Therapien erfordern zusätzliche finanzielle Ressourcen - Teil I (Antipsychotika). Neurotransmitter. 2001; 12 40-43
- 9 Fritze J. Innovative Therapien erfordern zusätzliche finanzielle Ressourcen - Teil II (Antidementiva). Neurotransmitter. 2001; 12 30-31
- 10 Fritze J, Gastpar M. Demenzkranke bitte nicht diskriminieren. Stellungnahme zur Kritik am Wirksamkeitsnachweis von Cholinesterasehemmern. Psychoneuro. 2004; 30 512-513
- 11 Fritze J, Schmauß M. Off-Label-Use: Der Fall Methylphenidat. Psychoneuro. 2003; 29 302-304
- 12 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000; 321 1371-1376
- 13 Gorman JM, Korotzer A, Su G. Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials. CNS Spectrums. 2002; 7 40-44
- 14 Gunnell D, Middleton N, Whitley E. et al. . Why are suicide rates rising in young men but falling in the elderly? A time-series analysis of trends in England and Wales 1950-1998. Soc Sci Med. 2003; 57 595-611
- 15 Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991-2000: Trend analysis. Br Med J. 2003; 326 1008-1011
- 16 Healy D. Lines of evidence on the risks of suizide with selective serotonin reuptake inhibitors. Psychother Psychosom. 2003; 72 71-79
- 17 Jureidini JN, Doecke Ch, Mansfiedl R, Haby M, Menkes B, Tonkin A. Efficacy and safety of antidepressants for children and adolescents. BMJ. 2004; 328 879-883
- 18 Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol. 2004; 19 149-155
- 19 Mann K, Lehert Ph, Morgan MY. The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis. Alcohol Clin Exp Res. 2004; 28 51-63
- 20 Olfson M, Shaffer D, Marcus SC. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003; 60 978-982
- 21 Rihmer Z. Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur Psychiat. 2001; 16 406-409
- 22 Svensson S, Mansfield PR. Escitalopram: superior to citalopram or a chiral chimera?. Psychother Psychosom. 2004; 73 10-16
- 23 Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine Study Group . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA. 2004; 291 317-324